Clinical Trials Directory

Trials / Completed

CompletedNCT05408676

Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer Surgery

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
198 (actual)
Sponsor
Fudan University · Academic / Other
Sex
Female
Age
18 Years – 64 Years
Healthy volunteers
Not accepted

Summary

Breast cancer is one of the three most common cancers worldwide, and the primary treatment method is surgery.Since most patients are non-smokers who use opioids in the postoperative period, which are known risk factors for postoperative nausea and vomiting (PONV) according to the Apfel Risk Score. Breast surgery was identified as a strong risk factor for PONV. According to the previous studies, the incidence of PONV is 30-70% in patients undergoing the breast cancer surgery, which not only gives patients unpleasant and painful experience, but also prolongs the hospital stays and delay patient discharge and adds to hospital costs. We compared the effects of dexamethasone alone vs. in combination with Pericardium 6 (P6) electrical stimulation or granisetron for inhibition of PONV in women undergoing breast cancer surgery.

Detailed description

186 patients who are planed to undergo elective breast cancer surgery under general anaesthesia into the following three groups: acupoint stimulation+dexamethasone (Group Acu, n=62), granisetron +dexamethasone (Group Gra, n=62), and dexamethasone alone (Group Dxm, n=62). The incidence of nausea, vomiting, and need for rescue antiemetics was recorded 2, 6, 24, and 48 h after surgery.

Conditions

Interventions

TypeNameDescription
DEVICEelectric stimulation therapyTranscutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)

Timeline

Start date
2022-06-10
Primary completion
2023-03-30
Completion
2023-05-02
First posted
2022-06-07
Last updated
2023-09-26

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05408676. Inclusion in this directory is not an endorsement.